FDA Takes Action Against Propoxyphene But Keeps It On The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA denies Public Citizen's request for withdrawal, instead mandating new studies to assess propoxyphene's link to overdoses and requiring a boxed warning and MedGuide.
You may also be interested in...
Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study
The opioid, marketed under the Darvon and Darvocet brands and in generic form, has the ignominious distinction of being the first drug pulled from the market based on results of a post-marketing safety study required under the 2007 law.
Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study
The opioid, marketed under the Darvon and Darvocet brands and in generic form, has the ignominious distinction of being the first drug pulled from the market based on results of a post-marketing safety study required under the 2007 law.
A Lack Of Data Keeps Propoxyphene On The Market ... For Now At Least
The lack of clear data substantiating the risk of fatal overdose with propoxyphene-containing drug products seems to have led FDA to its decision to keep the products on the market - and thus deny Public Citizen's petition for their withdrawal